Skip to ContentSkip to Navigation
How to find us A. Visser

Research interests

Lydia Visser received a PhD from the University of Groningen, the Netherlands in 2000 on her thesis titled: ‘Antibodies against leucocyte common antigen (CD45)-applications in immunomodulation’. She subsequently held a post-doctoral position at the Robards Research Institute of the University of Western Ontario in London (Ontario, Canada) on a project on the mechanism of anti-CD45RB tolerance induction. She is currently working at the department of Pathology and Medical Biology of the University Medical center Groningen as a scientist. She is as a PI part of the SALL. Her research is mainly focussed on the immunology of lymphoma and consists of interactions of tumor cells with the micro environment and signalling pathways in Hodgkin lymphoma and non-Hodgkin lymphomas.

 

Publications

Interaction between ERAP Alleles and HLA Class I Types Support a Role of Antigen Presentation in Hodgkin Lymphoma Development

Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma

B Cells as Prognostic Biomarker After Surgery for Colorectal Liver Metastases

Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis

Interim thymus and activation regulated chemokine versus interim F-18-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation

Microenvironment, cross-talk, and immune escape mechanisms

Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma

Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58

WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma

A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas

Read more